Document

Report
Immuno-Oncology Pipeline Targeting Checkpoints
Target
Phase1
CTLA-4
PD-1/
PD-L1
Phase 3
AZ (tremelimumab)
AZ(PD-1, MEDI0680, AMP-514))
MerckSerono (MSB0010718C)
Aplimumune/GSK(AMP-224)
BMS(BMS-936559)
KIR
CD137
Phase2
CureTech
(CT-011)
Market
BMS (iplimumab)
AZ (PD-L1,
MEDI4736)
Roche
(RG7446,
MPDL3280)
Merck
(pembrolizumab)
BMS (nivolumab)
BMS/Innate Pharma
(Lirimumab)
Pfizer (PF-05082566)
LAG-3
BMS (urelimab)
IMP (IMP321, LAG-3Ig)
CD40
CRUK (Chi Lob 7/4)
VLST/Pfizer (CP-870,893)
B7-H3
Servier(Macroenics (MAG271)
OX40
AZ (MEDI6469)
GITR
GITR(TRX518)
CD27
Celldex(CDX1127)
Astellas (ASKP1240)
PD-1/PD-L1 in preclinical: Agenus, Anaptysbio/TESARO, Aurigene/Pierre Fabre (AUNP-12. peptide)

similar documents